The pharmacological properties and therapeutic use of apomorphine.

Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry
Samo Ribarič

Abstract

Apomorphine (APO) is an aporphine derivative used in human and veterinary medicine. APO activates D₁, D(2S), D(2L), D₃, D₄, and D₅ receptors (and is thus classified as a non-selective dopamine agonist), serotonin receptors (5HT(1A), 5HT(2A), 5HT(2B), and 5HT(2C)), and α-adrenergic receptors (α(1B), α(1D), α(2A), α(2B), and α(2C)). In veterinary medicine, APO is used to induce vomiting in dogs, an important early treatment for some common orally ingested poisons (e.g., anti-freeze or insecticides). In human medicine, it has been used in a variety of treatments ranging from the treatment of addiction (i.e., to heroin, alcohol or cigarettes), for treatment of erectile dysfunction in males and hypoactive sexual desire disorder in females to the treatment of patients with Parkinson's disease (PD). Currently, APO is used in patients with advanced PD, for the treatment of persistent and disabling motor fluctuations which do not respond to levodopa or other dopamine agonists, either on its own or in combination with deep brain stimulation. Recently, a new and potentially important therapeutic role for APO in the treatment of Alzheimer's disease has been suggested; APO seems to stimulate Aβ catabolism in an animal model and cell culture...Continue Reading

References

Nov 1, 1992·Clinical Pharmacology and Therapeutics·S T GancherW R Woodward
Oct 1, 1991·Clinical Neuropharmacology·U BonuccelliA Muratorio
Jun 1, 1990·Journal of Veterinary Pharmacology and Therapeutics·R ScherklH H Frey
Aug 1, 1989·Annals of Neurology·S T GancherJ G Nutt
Aug 1, 1986·Acta Neurologica Scandinavica·P K MölsäU K Rinne
Jan 1, 1986·Journal of Neural Transmission·F Gonzales-RiosJ Costentin
Jan 1, 1995·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·D MuguetG Chazot
Mar 1, 1995·Acta Neurologica Scandinavica·P K MölsäU K Rinne
Apr 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·A J HughesG M Stern
Apr 1, 1996·Clinical Neuropharmacology·G Linazasoro
Jul 18, 1996·European Journal of Pharmacology·M GassenM B Youdim
Jun 27, 1997·The Journal of Biological Chemistry·C Wild-BodeC Haass
May 29, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·M MerelloR Leiguarda
Jan 7, 2000·The American Journal of Pathology·G K GourasN R Relkin
Sep 29, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·W Poewe, G K Wenning
Dec 16, 2000·The Journal of Biological Chemistry·T TaniguchiC Tanaka
Jun 7, 2001·Proceedings of the National Academy of Sciences of the United States of America·A AlonsoK Iqbal
Jun 8, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·J E Ahlskog, M D Muenter
Sep 8, 2001·The Journal of Urology·D FedeleUNKNOWN Diade Study Group
Jan 5, 2002·Neurobiology of Aging·R E Mrak, W S Griffin
Jan 22, 2002·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·A StefaniP Stanzione
Jan 31, 2002·Journal of Molecular Neuroscience : MN·C Glabe
Oct 3, 2002·Journal of Neurochemistry·Olivier BoutaudJohn A Oates
Feb 28, 2003·Journal of Neuroscience Research·Alberto Gómez-RamosJesús Avila
Jun 26, 2003·International Journal of Impotence Research·C G Stief
Apr 21, 2004·Journal of Alzheimer's Disease : JAD·Domenico Praticò, Syun Sung
Aug 25, 2004·Drugs & Aging·Dirk DeleuMargaret G Northway
Oct 27, 2004·Journal of Neuroinflammation·Yuemang YaoDomenico Praticò
Nov 19, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Yasumasa OhyagiTakeshi Tabira
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Akira Tsuji
Jul 19, 2005·Neurobiology of Aging·Gunnar K GourasReisuke H Takahashi

❮ Previous
Next ❯

Citations

Oct 12, 2012·Der Urologe. Ausg. A·L RinnabF Zengerling
Dec 18, 2013·European Journal of Pharmacology·Hitoshi KakiuchiKensuke Orito
Dec 23, 2015·Assay and Drug Development Technologies·Joel A Morales-RosadoEric W Klee
Apr 29, 2014·Chemical Biology & Drug Design·Shashikanth PonnalaWayne W Harding
Jun 27, 2014·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·X YuX Hou
Jun 4, 2013·Neuroscience Letters·Roi TreisterElon Eisenberg
Apr 24, 2014·Behavioural Pharmacology·Darakhshan J Haleem, Muhammad Farhan
Jan 13, 2018·Clinical Drug Investigation·Manon AuffretMarc Vérin
Dec 20, 2019·Journal of Computational Biology : a Journal of Computational Molecular Cell Biology·Daniele Pepe, Jin Hwan Do
May 15, 2018·Current Medicinal Chemistry·Seyed Mohammad NabaviEduardo Sobarzo-Sánchez
Jun 18, 2020·Life·Carla FerreiraAlexandre Quintas
Oct 17, 2018·Neural Regeneration Research·Luis Enrique Arroyo-GarciaGonzalo Flores
Feb 14, 2015·CNS Drugs·Allison Boyle, William Ondo
Aug 20, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Louiza Belkacemi, Nissar A Darmani
Apr 18, 2021·Autonomic Neuroscience : Basic & Clinical·Louiza BelkacemiNissar A Darmani
Aug 8, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ghada Ali, Gregory D Cuny
Aug 21, 2021·Cellular and Molecular Neurobiology·Tony HeurtauxMichel Mittelbronn
Aug 26, 2021·Journal of Veterinary Emergency and Critical Care·Terri E Eurell, Rachel E Peacock

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.